123 related articles for article (PubMed ID: 3829426)
1. The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients.
Malmendier CL; Delcroix C; Lontie JF
Clin Chim Acta; 1987 Jan; 162(2):221-7. PubMed ID: 3829426
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.
Malmendier CL; Delcroix C
Atherosclerosis; 1985 May; 55(2):161-9. PubMed ID: 3924068
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Lehtonen A; Viikari J
Artery; 1982; 10(5):353-67. PubMed ID: 7181678
[TBL] [Abstract][Full Text] [Related]
4. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.
Shepherd J; Packard CJ; Bicker S; Lawrie TD; Morgan HG
N Engl J Med; 1980 May; 302(22):1219-22. PubMed ID: 7366673
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Weisweiler P; Merk W; Jacob B; Schwandt P
Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
[TBL] [Abstract][Full Text] [Related]
6. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
Leren TP; Hjermann I; Berg K; Leren P; Foss OP; Viksmoen L
Atherosclerosis; 1988 Oct; 73(2-3):135-41. PubMed ID: 3056429
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
Sommariva D; Bonfiglioli D; Pogliaghi I; Cabrini E; Fasoli A
Pharmacol Res Commun; 1984 Aug; 16(8):809-20. PubMed ID: 6593751
[TBL] [Abstract][Full Text] [Related]
9. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia.
Weisweiler P
Metabolism; 1989 Mar; 38(3):271-4. PubMed ID: 2918846
[TBL] [Abstract][Full Text] [Related]
10. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.
Caslake MJ; Packard CJ; Gaw A; Murray E; Griffin BA; Vallance BD; Shepherd J
Arterioscler Thromb; 1993 May; 13(5):702-11. PubMed ID: 8485122
[TBL] [Abstract][Full Text] [Related]
12. Cholestyramine plus pectin in treatment of patients with familial hypercholesterolemia.
Schwandt P; Richter WO; Weisweiler P; Neureuther G
Atherosclerosis; 1982 Sep; 44(3):379-83. PubMed ID: 7150399
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
[TBL] [Abstract][Full Text] [Related]
14. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo.
Thompson GR; Soutar AK; Spengel FA; Jadhav A; Gavigan SJ; Myant NB
Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2591-5. PubMed ID: 6264482
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.
Mellies MJ; Stein EA; Khoury P; Lamkin G; Glueck CJ
Atherosclerosis; 1987 Jan; 63(1):57-64. PubMed ID: 3548734
[TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
[TBL] [Abstract][Full Text] [Related]
17. Cholestyramine in type IIa hyperlipoproteinemia. Is low-dose treatment feasible?
Angelin B; Einarsson K
Atherosclerosis; 1981; 38(1-2):33-8. PubMed ID: 7470203
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate affects the compositions of lipoproteins.
Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
[TBL] [Abstract][Full Text] [Related]
19. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
Raslová K; Dubovská D; Mongiellová V; Trnovec T
Eur J Clin Pharmacol; 1997; 52(2):101-6. PubMed ID: 9174678
[TBL] [Abstract][Full Text] [Related]
20. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Lorimer AR; Packard CJ; Shepherd J
Metabolism; 1989 Feb; 38(2):153-8. PubMed ID: 2643751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
